Connection

Michael Hallek to Purines

Back to Details
This is a "connection" page, showing publications Michael Hallek has written about Purines.
Michael Hallek
Connection Strength
1.216
Purines
  1. Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib. Drug Des Devel Ther. 2018; 12:2577-2590.
    View in: PubMed
    Score: 0.481
  2. Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia. J Clin Oncol. 2019 06 01; 37(16):1391-1402.
    View in: PubMed
    Score: 0.126
  3. Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib phase-3 trials. Leuk Lymphoma. 2019 06; 60(6):1438-1446.
    View in: PubMed
    Score: 0.122
  4. Venetoclax after idelalisib: relevant progress for CLL. Blood. 2018 04 12; 131(15):1632-1633.
    View in: PubMed
    Score: 0.117
  5. CLL2-BXX Phase II trials: sequential, targeted treatment for eradication of minimal residual disease in chronic lymphocytic leukemia. Future Oncol. 2018 Mar; 14(6):499-513.
    View in: PubMed
    Score: 0.116
  6. Chronic lymphocytic leukaemia. Lancet. 2018 04 14; 391(10129):1524-1537.
    View in: PubMed
    Score: 0.116
  7. Targeting of B-cell receptor signalling in B-cell malignancies. J Intern Med. 2017 11; 282(5):415-428.
    View in: PubMed
    Score: 0.109
  8. Sensitive Detection of the Natural Killer Cell-Mediated Cytotoxicity of Anti-CD20 Antibodies and Its Impairment by B-Cell Receptor Pathway Inhibitors. Biomed Res Int. 2018; 2018:1023490.
    View in: PubMed
    Score: 0.029
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.